Switch to:
More From Other Websites
Repros (RPRX) Q4 Earnings: What's in Store for the Stock? Mar 07 2017
REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Feb 02 2017
Repros Announces New CEO Feb 02 2017
FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the... Jan 30 2017
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of... Dec 19 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Dec 19 2016
Repros to Meet with the FDA for Phase III Proellex Program Dec 13 2016
How Bonanza Creek Energy Inc (BCEI) Stacks Up In Relation to Its Peers Dec 13 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Dec 12 2016
7 Companies That Destroyed Shareholders Last Week Dec 10 2016
Repros Therapeutics Drops on FDA Vote Dec 07 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Dec 07 2016
10 Major Pharma and FDA Catalysts Coming in December Dec 05 2016
REPROS THERAPEUTICS INC. Financials Nov 17 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Nov 15 2016
Repros (RPRX) Reports Positive Top-Line Data on Proellex Nov 15 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Nov 14 2016
Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus Nov 09 2016
REPROS THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report Nov 09 2016
Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results Nov 08 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition Nov 08 2016
What to Expect from Repros (RPRX) This Earnings Season Nov 03 2016
Repros' Secondary Hypogonadism Drug under Review in EU Oct 10 2016
Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European... Oct 05 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Oct 05 2016
Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the... Sep 12 2016
Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results Aug 09 2016
Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism... Jun 01 2016
Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board May 16 2016
Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results May 10 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK